Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels greater than or equal to 500 mg/dL and less than or equal to 2000 mg/dL.

Next Previous
Trial Profile

Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels greater than or equal to 500 mg/dL and less than or equal to 2000 mg/dL.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms MARINE
  • Sponsors Amarin Corporation

    • Most Recent Events

    • 16 Jun 2020 According to an Amarin Corporation media release,company has a settlement agreement with Apotex that resolves patent litigation that would have resulted from the previously disclosed ANDA filed by Apotex and amended in May 2020 seeking approval of a generic form of VASCEPA based on the MARINE study. As part of the settlement agreement, Apotex may not sell a generic of VASCEPA in the US until August 9, 2029 or earlier under certain customary circumstances.
    • 28 Nov 2018 According to a Cardax Pharmaceuticals media release, Paresh N. Soni, M.D., Ph.D led the development of this clinical trial and regulatory strategy.
    • 01 Nov 2016 Results (n=215) of subgroup analyses of MARINE and ANCHOR trials published in the American Journal of Cardiology (2016).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top